Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
Rhea-AI Summary
Bio-Path Holdings (NASDAQ: BPTH) announced it will host a conference call and audio webcast on November 15, 2024, at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide a business overview. The company develops DNAbilize®, an RNAi nanoparticle drug technology administered through intravenous transfusion. Their pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. They're also preparing an IND filing for BP1003, a STAT3 inhibitor.
Positive
- Multiple drug candidates in clinical development phases
- Proprietary DNAbilize® technology platform
- Diversified pipeline targeting both blood cancers and solid tumors
Negative
- None.
News Market Reaction
On the day this news was published, BPTH declined 1.96%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview.
To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When will Bio-Path Holdings (BPTH) report Q3 2024 earnings?
What clinical trials does Bio-Path Holdings (BPTH) currently have ongoing?
What is Bio-Path Holdings' (BPTH) main technology platform?
